Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DURECT CORPDRRX · Entity 75335 | Director | June 17, 2020 | June 18, 2020 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | September 09, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DURECT CORP
Report date June 17, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2030-06-17 | Direct | 55,000 |
Reported balance
After 2020-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-17 · Grant · Acquired 55,000 · Balance 55,000 F1: 100% of the total shares of this Grant Dated June 17, 2020 shall vest on the day before the first year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the total shares of this Grant Dated June 17, 2020 shall vest on the day before the first year anniversary of the Grant Date.
Vistagen Therapeutics, Inc.
Report date September 09, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2035-09-09 | Direct | 17,600 |
Reported balance
After 2025-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-09 · Grant · Acquired 17,600 · Balance 17,600 F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SCICLONE PHARMACEUTICALS INC
Report date October 13, 2017 · Filed October 16, 2017
Section 16 reporting ended · disclosed 2017-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 1
1 source rowRow 1 · 2017-10-13 · Disposition to issuer · Disposed 135,000 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2018-06-10 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F1: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2008), and became immediately exercisable and vested in full as of June 9, 2009. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2019-06-09 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F3: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2020-06-10 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F4: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2021-06-30 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F5: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2022-06-07 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F6: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2023-06-27 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F7: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2024-06-12 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F8: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.15 · Expires 2025-06-11 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F9: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F10: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2008), and became immediately exercisable and vested in full as of June 9, 2009.
F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
F3: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010.
F4: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011.
F5: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012.
F6: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.
F7: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
F8: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
F9: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
F10: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,232 | $0.70 | $856.49 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 16 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 60,320 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,000 | $0.69 | $694.40 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 15 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 59,088 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 400 | $0.69 | $277.64 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 14 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 58,088 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 895 | $0.69 | $621.13 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 13 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 57,688 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 779 | $0.69 | $538.37 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 12 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 56,793 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 569 | $0.69 | $392.95 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 11 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 56,014 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 489 | $0.69 | $337.51 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 10 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 55,445 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,195 | $0.69 | $824.55 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 9 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 54,956 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 3,100 | $0.69 | $2,138.38 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 8 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 53,761 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.69 | $137.62 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 7 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 50,661 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 699 | $0.69 | $478.82 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 6 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 50,461 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 900 | $0.68 | $613.35 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 5 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 49,762 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 287 | $0.68 | $195.56 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 4 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 48,862 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 2,995 | $0.68 | $2,037.50 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 48,575 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 380 | $0.68 | $258.48 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 2 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 45,580 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.68 | $136.08 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 45,200 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 15, 2019 14:43 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 2,200 | $0.71 | $1,557.60 |
DisclosureSEC source: 0001082038-19-000013 · edgardoc.xml · nonDerivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 95,000 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 15, 2019 14:43 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 6,500 | $0.70 | $4,581.20 |
DisclosureSEC source: 0001082038-19-000013 · edgardoc.xml · nonDerivative · entry 2 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 92,800 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 15, 2019 14:43 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 900 | $0.70 | $633.87 |
DisclosureSEC source: 0001082038-19-000013 · edgardoc.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 86,300 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 14, 2019 Filed Mar 14, 2019 17:22 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | PurchaseCommon Stock | 7,920 | $1.27 | $10,086.12 |
DisclosureSEC source: 0001415889-19-000322 · form4-03142019_020358.xml · nonDerivative · entry 2 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Jon S. Saxe and Myrna G. Marshall 1997 Trust Disclosed balance after: 20,000 Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 17:22 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | PurchaseCommon Stock | 12,080 | $1.26 | $15,201.47 |
DisclosureSEC source: 0001415889-19-000322 · form4-03142019_020358.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Jon S. Saxe and Myrna G. Marshall 1997 Trust Disclosed balance after: 12,080 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $81.51 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 12 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 45,000 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.82 | $244.59 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 11 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 44,900 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $163.16 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 10 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 44,600 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $163.18 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 9 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 44,400 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 600 | $0.82 | $489.60 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 8 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 44,200 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $81.61 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 7 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 43,600 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $81.63 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 6 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 43,500 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $163.30 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 5 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 43,400 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 800 | $0.82 | $653.36 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 4 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 43,200 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $81.68 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 42,400 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $81.69 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 2 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 42,300 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:37 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 900 | $0.82 | $735.48 |
DisclosureSEC source: 0001082038-19-000006 · edgardoc.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 42,200 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 600 | $0.82 | $490.38 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 30 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 41,300 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.82 | $245.40 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 29 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 40,700 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 600 | $0.82 | $491.04 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 28 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 40,400 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $163.72 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 27 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 39,800 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 625 | $0.82 | $511.94 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 26 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 39,600 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 600 | $0.82 | $491.52 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 25 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 38,975 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $163.86 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 24 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 38,375 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $81.94 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 23 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 38,175 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 400 | $0.82 | $327.80 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 22 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 38,075 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.82 | $245.88 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 21 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 37,675 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 3,441 | $0.82 | $2,821.28 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 20 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 37,375 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 4,600 | $0.82 | $3,772.00 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 19 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 33,934 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 748 | $0.82 | $613.51 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 18 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 29,334 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $164.06 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 17 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 28,586 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.82 | $82.04 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 16 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 28,386 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,800 | $0.82 | $1,477.80 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 15 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 28,286 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:36 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.82 | $164.24 |
DisclosureSEC source: 0001082038-19-000005 · edgardoc.xml · nonDerivative · entry 14 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 26,486 F1 · ownership.nature: Held by Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.